About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: KERX
- CUSIP: 49251510
- Previous Close: $4.99
- 50 Day Moving Average: $5.48
- 200 Day Moving Average: $5.22
- 52-Week Range: $3.17 - $7.80
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.82
- P/E Growth: -0.03
- Market Cap: $505.43M
- Outstanding Shares: 105,960,000
- Beta: 4.93
- Net Margins: -584.76%
- Return on Equity: -270.26%
- Return on Assets: -67.88%
Companies Related to Keryx Biopharmaceuticals:
- Debt-to-Equity Ratio: 5.69%
- Current Ratio: 8.75%
- Quick Ratio: 7.42%
What is Keryx Biopharmaceuticals' stock symbol?
Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."
Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?
12 brokerages have issued 1 year target prices for Keryx Biopharmaceuticals' shares. Their predictions range from $2.50 to $16.00. On average, they anticipate Keryx Biopharmaceuticals' stock price to reach $8.83 in the next twelve months.
When will Keryx Biopharmaceuticals announce their earnings?
Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Keryx Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
According to Zacks Investment Research, "Keryx’s top line is driven by sales of its lead product, Auryxia. We are encouraged by the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication. Moreover, the IDA market holds great potential. However, the company took a hit due to an imminent interruption in the supply of Auryxia in August, because of issues related to the conversion of the active pharmaceutical ingredient (API) into the finished product by its contract manufacturer. Consequently, the company withdrew its guidance for 2016. The supply issue is not expected to be resolved any time soon and will lead to a significant decline in sales. Moreover, it will continue to hurt on Keryx’s shares until supply normalizes. Given that the company is heavily dependent on Auryxia for growth, this development is concerning. Loss estimate have been rising ahead of the company’s Q3 earnings release." (11/1/2016)
JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)
Maxim Group analysts commented, "We make modest adjustments to our model, but our DCF-derived target price remains €48." (8/1/2016)
FBR & Co analysts commented, "We are previewing Keryx’s 2Q16 financial results, following an update with management and analysis of IMS script data for Keryx’s approved drug, Auryxia (ferric citrate). KERX shares are up approximately 85% since our upgrade on February 29, 2016, versus a gain of ~12% for the S&P 500 Index, which reflects our thesis and KERX’s continued execution. In 2Q16, IMS scripts grew ~37% to 7,164 scripts, compared with 1Q16 script growth of ~16% to 5,217 scripts. Assuming a capture rate of 57%, we think total script growth could reach 12,565 for the quarter. We had an opportunity to speak with management and discuss the company’s corporate progress and provide the following takeaways: (1) we believe the 2Q16 IMS script growth highlights continued execution with the Auryxia launch; (2) we see a potential tailwind for Auryxia sales from a price increase in 2H16; and (3) long term, we believe the expansion of Auryxia’s use in non-dialysis Iron Deficiency Anemia (IDA) patients has significant potential to increase prescribing physician awareness and expand the market opportunity for the drug." (7/25/2016)
Who owns Keryx Biopharmaceuticals stock?
Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Abrams Capital Management L.P. (5.40%), State Street Corp (2.73%), FMR LLC (2.33%), Deerfield Management Co. (1.22%), Royce & Associates LP (0.24%) and Iridian Asset Management LLC CT (0.22%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, James F Oliviero III, John F Neylan, Michael P Tarnok, Ron Bentsur and Scott A Holmes.
Who sold Keryx Biopharmaceuticals stock? Who is selling Keryx Biopharmaceuticals stock?
Keryx Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Royce & Associates LP and Frontier Wealth Management LLC. Company insiders that have sold Keryx Biopharmaceuticals stock in the last year include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes.
Who bought Keryx Biopharmaceuticals stock? Who is buying Keryx Biopharmaceuticals stock?
Keryx Biopharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., Iridian Asset Management LLC CT, Old West Investment Management LLC, Advantage Investment Management LLC, Clough Capital Partners L P and Metropolitan Life Insurance Co. NY. Company insiders that have bought Keryx Biopharmaceuticals stock in the last two years include Greg Madison, Michael P Tarnok and Scott A Holmes.
How do I buy Keryx Biopharmaceuticals stock?
Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Keryx Biopharmaceuticals stock cost?
One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $4.77.